Do analysts prefer APVO or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, APVO or ABP?

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is APVO or ABP more profitable?

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Abpro N/A N/A -344.76%

Which has higher valuation & earnings, ADIL or ABP?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is ADIL or ABP more profitable?

Abpro's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Abpro N/A N/A -344.76%

Do analysts recommend PULM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, PULM or ABP?

Pulmatrix has higher revenue and earnings than Abpro. Pulmatrix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmatrix $7.81M 0.77 -$5.16M -$1.23 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is PULM or ABP more profitable?

Abpro's return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -107.84% -91.58% Abpro N/A N/A -344.76%

Does the media favor PULM or ABP?

In the previous week, Pulmatrix had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Pulmatrix and 1 mentions for Abpro. Pulmatrix's average media sentiment score of 1.21 beat Abpro's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmatrix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abpro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings & valuation, APM or ABP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group N/A N/A -$1.36M N/A N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is APM or ABP more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Abpro N/A N/A -344.76%

Does the media favor APM or ABP?

In the previous week, Aptorum Group had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Abpro. Aptorum Group's average media sentiment score of 0.30 beat Abpro's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abpro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ABP or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ABP or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Mustang Bio N/A N/A -$1.92M -$0.48 N/A

Is ABP or MBIO more profitable?

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Mustang Bio N/A -35.38% -16.36%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 06/26/2026

Compare

ABP vs. APVO, ADIL, PULM, APM, and MBIO

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include Aptevo Therapeutics (APVO), Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Aptorum Group (APM), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry.

How does Abpro compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.89 beat Abpro's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Abpro	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Abpro	N/A	N/A	-344.76%

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aptevo Therapeutics and Abpro tied by winning 5 of the 10 factors compared between the two stocks.

How does Abpro compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Adial Pharmaceuticals presently has a consensus target price of $17.17, suggesting a potential upside of 564.09%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Adial Pharmaceuticals is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 13.7% of Abpro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for Abpro. Adial Pharmaceuticals' average media sentiment score of 0.44 beat Abpro's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
Abpro	Neutral

Abpro's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Abpro	N/A	N/A	-344.76%

Summary

Adial Pharmaceuticals and Abpro tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Pulmatrix had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Pulmatrix and 1 mentions for Abpro. Pulmatrix's average media sentiment score of 1.21 beat Abpro's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmatrix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abpro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abpro's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
Abpro	N/A	N/A	-344.76%

Pulmatrix has higher revenue and earnings than Abpro. Pulmatrix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.77	-$5.16M	-$1.23	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Summary

Pulmatrix beats Abpro on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Aptorum Group had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Abpro. Aptorum Group's average media sentiment score of 0.30 beat Abpro's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abpro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 13.7% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Abpro	N/A	N/A	-344.76%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Summary

Aptorum Group beats Abpro on 5 of the 7 factors compared between the two stocks.

How does Abpro compare to Mustang Bio?

Abpro (NASDAQ:ABP) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

23.3% of Abpro shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Mustang Bio	N/A	-35.38%	-16.36%

In the previous week, Mustang Bio had 1 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for Abpro. Mustang Bio's average media sentiment score of 0.43 beat Abpro's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Mustang Bio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro and Mustang Bio tied by winning 5 of the 10 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.64B	$6.80B	$12.48B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.12	20.98	25.72	24.65
Price / Sales	N/A	344.19	545.41	102.66
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	-0.06	8.74	10.94	6.52
Net Income	-$7.23M	$23.81M	$3.57B	$336.61M
7 Day Performance	N/A	3.42%	2.21%	1.24%
1 Month Performance	N/A	1.43%	0.55%	0.28%
1 Year Performance	-91.82%	69.73%	36.44%	30.62%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	0.0357 of 5 stars	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
APVO Aptevo Therapeutics	1.3606 of 5 stars	$4.80 +5.7%	N/A	-91.8%	$5.66M	N/A	N/A	50	News Coverage Positive News
ADIL Adial Pharmaceuticals	2.3189 of 5 stars	$2.75 +8.3%	$17.17 +524.2%	-69.1%	$5.44M	N/A	N/A	20	Gap Down
PULM Pulmatrix	1.2753 of 5 stars	$1.50 +0.7%	N/A	-76.4%	$5.44M	$7.81M	N/A	20	Positive News Short Interest Decrease
APM Aptorum Group	0.6963 of 5 stars	$0.87 +3.3%	N/A	-20.4%	$5.35M	$430K	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. APVO, ADIL, PULM, APM, and MBIO

How does Abpro compare to Aptevo Therapeutics?

Summary

How does Abpro compare to Adial Pharmaceuticals?

Summary

How does Abpro compare to Pulmatrix?

Summary

How does Abpro compare to Aptorum Group?

Summary

How does Abpro compare to Mustang Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. APVO, ADIL, PULM, APM, and MBIO

How does Abpro compare to Aptevo Therapeutics?

Which has better earnings & valuation, APVO or ABP?

Does the media favor APVO or ABP?

Do analysts prefer APVO or ABP?

Is APVO or ABP more profitable?

Do insiders and institutionals have more ownership in APVO or ABP?

Summary

How does Abpro compare to Adial Pharmaceuticals?

Do analysts prefer ADIL or ABP?

Do insiders & institutionals have more ownership in ADIL or ABP?

Which has higher valuation & earnings, ADIL or ABP?

Does the media prefer ADIL or ABP?

Is ADIL or ABP more profitable?

Summary

How does Abpro compare to Pulmatrix?

Do analysts recommend PULM or ABP?

Does the media favor PULM or ABP?

Do institutionals and insiders have more ownership in PULM or ABP?

Is PULM or ABP more profitable?

Which has stronger earnings and valuation, PULM or ABP?

Summary

How does Abpro compare to Aptorum Group?

Does the media favor APM or ABP?

Do analysts prefer APM or ABP?

Do insiders and institutionals believe in APM or ABP?

Is APM or ABP more profitable?

Which has stronger earnings & valuation, APM or ABP?

Summary

How does Abpro compare to Mustang Bio?

Do insiders and institutionals have more ownership in ABP or MBIO?

Which has preferable valuation & earnings, ABP or MBIO?

Is ABP or MBIO more profitable?

Does the media refer more to ABP or MBIO?

Do analysts prefer ABP or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools